You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

286 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Blinatumomab - Front-line Consolidation for B-cell Precursor Acute Lymphoblastic Leukemia
Nov 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
May 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
May 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative
May 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
May 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
Jun 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    abiraterone
ODB - General Benefit
    prednisone
Jul 2025
Regimen
Intent: Adjuvant, Curative, Palliative
Jul 2025

Pages